Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Abacus Medicine acquires Delfarma in Poland

PRIVATESep 15, 2026•1 day ago

Acquiring Company

Abacus Medicine

Acquired Company

Delfarma

CopenhagenPolandBiotechnologyHealth CareMedicalManufacturingBiotechnologyHealth CarePharmaceutical

Description

Abacus Medicine has successfully acquired Delfarma, a prominent pharmaceutical company in Poland. This acquisition aims to enhance Abacus Medicine's presence in the European market. Delfarma's established operations align well with Abacus's vision for expansion and improved healthcare access.

Company Information

Company

Abacus Medicine

Location

Copenhagen, Capital Region Of Denmark, Denmark

About

Abacus Medicine is a leading global healthcare company that specializes in pharmaceutical distribution. They focus on improving patient access to medicines worldwide. The company works with various stakeholders to deliver healthcare solutions efficiently.

Don't miss Abacus Medicine's next move

Get an email the moment Abacus Medicine makes an acquisition, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Abacus Medicine's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed

Frequently asked

Who acquired Delfarma?

Delfarma was acquired by Abacus Medicine, based in Copenhagen. The deal was reported on September 15, 2026. Abacus Medicine is a leading global healthcare company that specializes in pharmaceutical distribution. They focus on improving patient access to medicines worldwide. Abacus Medicine is privately held and operates in Biotechnology.

When did Abacus Medicine acquire Delfarma?

Abacus Medicine's acquisition of Delfarma was reported on September 15, 2026. Abacus Medicine has successfully acquired Delfarma, a prominent pharmaceutical company in Poland. This acquisition aims to enhance Abacus Medicine's presence in the European market. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.

What does Delfarma do?

Delfarma is a Polish pharmaceutical company involved in the distribution and supply of medicines across the region. They are known for their commitment to quality and efficiency in delivering healthcare products. It is privately held, operating in Manufacturing, and is based in Poland.

This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.